SEATTLE--(BUSINESS WIRE)--Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patient in its Phase III trial of Litx for colorectal cancer metastatic to the liver (MCRC). The pivotal Phase III trial is the final trial required before Litx can be submitted to the U.S. Food and Drug Administration (FDA) for marketing approval. Initiation of the study follows an agreement reached in January 2007 with the FDA on a Special Protocol Assessment (SPA).
